A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
A phase 2/3 trial testing BEBT-209 in triple-negative breast cancer, now recruiting.
Overview
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer is a phase 2/3 interventional study registered as NCT07544056, led by BeBetter Med with Hunan Cancer Hospital and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, and recruiting when checked on 2026-09-11. Official title: A Randomised, Controlled, Open-label, Multi-centre, Phase IIb/III Clinical Study to Evaluate BEBT-209 Plus Carboplatin and Gemcitabine Versus Carboplatin Plus Gemcitabine in Locally Advanced or Metastatic Triple-Negative Breast Cancer. Planned enrolment is 446 participants (estimated). The study started in 2026-06-04 and primary completion is expected in 2030-06. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialStudy of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
Shares BEBT-209 and the tag ctgov-ingest.
- TrialPM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TrialA Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TrialFDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TrialA Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TreatmentFDA018-ADC
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TreatmentOleclumab
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TreatmentJSKN016
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.